Mechanisms of tamoxifen resistance

Alistair Ring(National Health Service), Mitch Dowsett(Institute of Cancer Research)

Endocrine Related Cancer

December 1, 2004

10.1677/erc.1.00776

Cited by 652

Related Papers

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial

|The Lancet|2007|1.5k

Relationship Between Quantitative Estrogen and Progesterone Receptor Expression and Human Epidermal Growth Factor Receptor 2 (HER-2) Status With Recurrence in the Arimidex, Tamoxifen, Alone or in Combination Trial

|Journal of Clinical Oncology|2008|464

Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer

|JAMA Oncology|2019|425

Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)

|Journal of Clinical Oncology|2017|411

Sex hormones and risk of breast cancer in premenopausal women: a collaborative reanalysis of individual participant data from seven prospective studies

|The Lancet Oncology|2013|403